(Q36113030)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

review article

1 reference

title

Optimal role of temozolomide in the treatment of malignant gliomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

0 references

Martin J van den Bent

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Monika E Hegi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Roger Stupp

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

1 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

Current Neurology and Neuroscience Reports

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

198-206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11910-005-0047-7

11 January 2020

exact match

0 references

cites work

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0047-7

Temozolomide chemotherapy in recurrent oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0047-7

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0047-7

Initial chemotherapy in gliomatosis cerebri.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0047-7

Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors

21 January 2018

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

1 reference

12 December 2020

First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia

1 reference

12 December 2020

A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy

1 reference

12 December 2020

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

12 December 2020

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

1 reference

12 December 2020

Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy

1 reference

12 December 2020

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

1 reference

12 December 2020

Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

1 reference

12 December 2020

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

1 reference

12 December 2020

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors

1 reference

12 December 2020

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

1 reference

12 December 2020

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

1 reference

12 December 2020

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

12 December 2020

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

12 December 2020

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients

1 reference

12 December 2020

Phase I. Trial of irinotecan and temozolomide in patients with solid tumors

1 reference

12 December 2020

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

12 December 2020

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

1 reference

12 December 2020

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

1 reference

12 December 2020

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

1 reference

12 December 2020

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

1 reference

12 December 2020

Clinical relevance of MGMT in the treatment of cancer

1 reference

12 December 2020

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

12 December 2020

Phase II trial of temozolomide in patients with progressive low-grade glioma

1 reference

12 December 2020

Phase I trial of temozolomide using an extended continuous oral schedule.

1 reference

12 December 2020

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

1 reference

12 December 2020

Temozolomide in the treatment of recurrent malignant glioma

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

1 reference

12 December 2020

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

1 reference

12 December 2020

Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase

1 reference

12 December 2020

MGMT: its role in cancer aetiology and cancer therapeutics

1 reference

12 December 2020

Current and future developments in the use of temozolomide for the treatment of brain tumours

1 reference

12 December 2020

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial

1 reference

12 December 2020

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

1 reference

12 December 2020

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

1 reference

12 December 2020

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

1 reference

12 December 2020

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

1 reference

12 December 2020

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.

1 reference

12 December 2020

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

12 December 2020

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.

1 reference

12 December 2020

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

1 reference

12 December 2020

Promises and controversies in the management of low-grade glioma

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

10.1007/S11910-005-0047-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15865885%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference